LEADING MARKETPLACE
FOR BIOPHARMACEUTICAL SURPLUS

Global Sales — Your Comprehensive Surplus Asset Solution

Whether you're decommissioning a research facility, upgrading manufacturing equipment, or disposing of excess laboratory instruments, Liquidity Services understands the specialized nature of biopharma asset sales. Our global marketplace connects your assets with qualified buyers throughout the pharmaceutical ecosystem, from contract research organizations to emerging biotech companies seeking cost-effective equipment solutions.

With Liquidity Services, you move nothing. We sell your assets in place, eliminating the complexities of relocating sensitive laboratories and manufacturing equipment. Our specialized biopharma team understands the unique value propositions of pharmaceutical equipment, from analytical instruments to bioreactors and cleanroom systems. When large facility closures or technology upgrades occur, we manage every aspect, including cataloging specialized assets, marketing them to qualified buyers, and handling transactions through final settlement while maintaining the chain of custody and documentation requirements.

Audit-ready, Compliant, and Secure

Biopharma asset disposal faces the industry's most rigorous compliance requirements, from FDA regulations to international export controls and environmental safety standards. Documentation, validation records, and audit trails are essential for regulatory compliance and risk management. By partnering with Liquidity Services, you ensure your surplus asset program meets pharmaceutical industry standards while removing internal resources from complex disposal processes. Our fully compliant workflow includes comprehensive documentation of asset history, validation status, and sale records, all maintained for regulatory audit requirements. We manage secure funds handling, international shipping compliance, and specialized documentation for controlled substances or regulated equipment. Our continuous screening process ensures buyers meet pharmaceutical industry standards and regulatory requirements, protecting your organization from compliance risks while maximizing asset recovery.

Turn Asset Management into a Strong Balance Sheet

Every research program conclusion, manufacturing process improvement, or facility upgrade generates surplus equipment that no longer serves your biopharma operations. Converting these specialized assets into capital while they retain market value immediately offsets research costs and boosts return on invested capital. Speed is particularly crucial in biopharma, where regulatory changes and technological advances can rapidly impact asset values.

Advance Sustainability Through Surplus Asset Management

An investment recovery program directly supports biopharmaceutical companies' sustainability commitments and environmental stewardship goals. By prioritizing equipment reuse and refurbishment over disposal, you extend the lifecycle of specialized pharmaceutical assets while reducing the environmental impact of new equipment manufacturing. Every instrument that finds a second life in pharmaceutical research or manufacturing prevents new production, avoiding the energy consumption and raw material extraction embedded in specialized equipment.

For biopharma companies facing increasing scrutiny over environmental impact, your surplus asset program provides quantifiable sustainability metrics. Through our network of qualified pharmaceutical buyers, specialized equipment continues serving drug discovery and development, supporting smaller research organizations and emerging markets while delivering documented environmental benefits that align with corporate sustainability reporting requirements and stakeholder expectations.